Our services

The Wegovy Injection in the UAE: What It Is, Who It Is For and How Treatment Works

Picture of Dr. Hecham Harb

Dr. Hecham Harb

Consultant Endocrinologist & Medical Director

Wegovy Injection in UAE - Price, Results, Eligibility & More

Select your location

Book Your Consultation

Quick answer

The Wegovy injection contains semaglutide and is approved for weight management in adults and in adolescents aged 12 and older. It is injected once a week, and your endocrinologist can increase the dose in steps from 0.25 mg towards 2.4 mg. In STEP 1, a 68-week clinical trial in adults with obesity or overweight, patients on 2.4 mg lost around 15% of their body weight on average. It is available in the UAE on prescription.

Key takeaways
  • The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes weight loss medication as an option for adults with a body mass index (BMI) of 30 or above, or 27 or above with a weight-related condition.
  • Treatment typically starts at 0.25 mg once a week, and each step towards 2.4 mg is reviewed with your endocrinologist at your monthly follow-up.
  • Digestive side effects such as nausea and diarrhoea are reported more often than others and can be particularly pronounced in the first few days at a new dose.
  • The prescribing information advises stopping the Wegovy injection at least two months before a planned pregnancy.
  • The Wegovy pill is a once-daily tablet containing the same active ingredient, semaglutide, with its own dose steps and instructions for taking it.
  • UAE pharmacy prices for the Wegovy injection run from AED 743.50 a month at 0.25 mg to AED 1,712 a month at 2.4 mg.
In one line: The Wegovy injection is also approved to lower the risk of heart attack and stroke in adults with overweight or obesity and established heart disease.

01  Introduction

Our endocrinologists prescribe the Wegovy injection for weight management alongside a reduced-calorie diet and increased physical activity.

The Wegovy injection is a prescription medication made by Novo Nordisk. Its active ingredient is semaglutide, which belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. It is injected under the skin once a week, using a pen.

In the UAE, the Wegovy injection is available on prescription at every strength from 0.25 mg to 2.4 mg. A 7.2 mg dose of Wegovy is not available in the UAE.

Semaglutide acts like GLP-1, a hormone that the gut releases after eating. GLP-1 helps regulate appetite, the release of insulin and how quickly the stomach empties. The Wegovy prescribing information describes semaglutide as binding to and activating the GLP-1 receptor.

By acting on this receptor, semaglutide can reduce appetite and the amount of food eaten, although the response differs from one patient to another.

The Wegovy injection is approved for weight management in adults, and in adolescents aged 12 and older with obesity. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes weight loss medication as an option for adults with a BMI of 30 or above, or 27 or above with a weight-related condition. This is general guidance, and what applies to you depends on the medication’s approved indication and your clinical assessment.

Examples of weight-related conditions include prediabetes, type 2 diabetes, high blood pressure, high cholesterol and obstructive sleep apnoea. Your endocrinologist will assess whether medication is appropriate based on your individual health and weight profile. Thyroid disease can affect metabolic rate and make weight management more difficult, but it is treatable once diagnosed. Insulin resistance often accompanies metabolic conditions that can affect weight management. It is also associated with increased waist circumference.

In SELECT, a large clinical trial in adults with established heart disease and overweight or obesity, patients taking the Wegovy injection had a lower risk of heart attack and stroke than patients taking a placebo.

Patients should not decide by themselves to start a GLP-1 medication. A doctor’s review is critical to ensure the treatment is safe and appropriate for the individual.

The prescribing information sets out five dose steps:

  • 0.25 mg once weekly in weeks 1 to 4
  • 0.5 mg once weekly in weeks 5 to 8
  • 1 mg once weekly in weeks 9 to 12
  • 1.7 mg once weekly in weeks 13 to 16
  • 2.4 mg once weekly from week 17
 

These timings are the earliest points at which the dose can be increased. Your endocrinologist will decide each increase with you. The prescribing information gives 2.4 mg or 1.7 mg once weekly as the maintenance dose. Our Wegovy dosage guide explains each step and what happens if you miss a dose.

The exact pen technique differs by device, so follow the instructions supplied with your prescribed pen. Our guide on how to inject weight loss medication covers the general steps.

Keep unopened pens refrigerated at 2–8°C. The permitted time outside the fridge varies by medication and pen type, so always check the leaflet supplied with your pen. The Wegovy pen instructions allow up to 28 days between 8°C and 30°C before the cap is removed. Our article on storing weight loss injections covers storage during the UAE summer.

In STEP 1, a Phase 3 clinical trial in adults with obesity or overweight, patients taking the Wegovy injection at 2.4 mg lost an average of around 15% of their total body weight over 68 weeks.

At Endocare, our endocrinologists typically observe weight loss of three to four kilos a month in patients on a medically supervised programme. Some patients start to see weight changes from around week two, while others take longer to respond. Early weight loss also does not necessarily continue at the same rate. Our guide on how long weight loss injections take to work explains the early weeks of treatment in more detail.

The digestive side effects reported in 5% or more of adults in the prescribing information include nausea, diarrhoea, vomiting, constipation, abdominal pain and indigestion. Headache, fatigue and dizziness are also reported at this rate. Not every patient experiences them. Side effects such as nausea or constipation can be particularly pronounced in the first few days at a new dose. They often improve as your body adjusts, although some symptoms last longer.

If you experience nausea or constipation, your endocrinologist can adjust the pace of dose increases and, where needed, prescribe medication to help manage these side effects. Our page on Wegovy side effects covers each side effect and how your endocrinologist can manage it.

Seek medical advice immediately if you have severe stomach pain that does not go away, with or without vomiting, as this can be a sign of pancreatitis. Seek medical advice immediately if you have pain in the upper right side of your abdomen, fever or yellowing of the skin or eyes, which can be signs of a gallbladder problem.

Do not use the Wegovy injection if you or a member of your family has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2. The prescribing information lists both as reasons not to use semaglutide, together with a previous serious allergic reaction to it.

If you are planning a pregnancy, stop the Wegovy injection at least two months beforehand. The prescribing information gives this advice because of the long washout period for semaglutide. Do not use the Wegovy injection together with Ozempic, the Wegovy pill or any other GLP-1 medication.

Your endocrinologist will also ask about any history of pancreatitis, gallbladder disease or severe digestive problems, because the prescribing information carries specific warnings for each. Tell your endocrinologist and your anaesthetist about the Wegovy injection before any planned procedure that needs sedation or a general anaesthetic. Semaglutide slows the emptying of the stomach, which can increase the risk of inhaling stomach contents during anaesthesia.

The Wegovy pill is a once-daily tablet that contains the same active ingredient, semaglutide. It is taken in the morning on an empty stomach. The morning timing comes from the US prescribing information, and the UK product information sets no time of day. Its doses rise in steps from 1.5 mg to 25 mg.

In OASIS 4, a Phase 3 clinical trial in adults with obesity or overweight, patients taking the Wegovy pill lost an average of around 17% of their total body weight over 64 weeks. The Emirates Drug Establishment approved the Wegovy pill on 1 June 2026 for long-term weight management in adults with obesity, or overweight with weight-related conditions.

Neither option is necessarily better. The right choice depends on your individual assessment, how well you tolerate treatment and what you can realistically sustain long term. Your endocrinologist will work through these factors with you. Our page on weight loss pills covers the tablet options in more detail.

UAE pharmacy prices for the Wegovy injection are AED 743.50 a month at 0.25 mg and at 0.5 mg, AED 1,145.50 at 1 mg, AED 1,440 at 1.7 mg and AED 1,712 at 2.4 mg. The price you pay depends on the dose your endocrinologist prescribes. Endocare adds no markup to the official pharmacy price of your medication.

Wegovy treatment at Endocare is offered as part of our medical weight loss programme, starting at AED 1,790 for the first month and AED 1,990 per month thereafter. The programme includes your medication, unlimited specialist consultations and one-to-one coaching during the month, body composition analysis at every visit, scheduled blood tests and free medication delivery across the UAE. For a detailed breakdown, see our page on the Wegovy price in the UAE. Our page on weight loss injection costs in the UAE compares the Wegovy injection with Mounjaro and Ozempic.

This table compares the Wegovy injection with Mounjaro, the Wegovy pill and Foundayo. These figures come from separate clinical trials with different participants and durations. They give a general comparison and do not rank the medications directly.

OptionHow it worksRouteAverage weight loss in trials (% of body weight)
The Wegovy injection (semaglutide)Acts on the GLP-1 receptorOnce-weekly injectionAround 15% over 68 weeks at 2.4 mg (STEP 1 trial)
Mounjaro (tirzepatide)Acts on the GIP and GLP-1 receptorsOnce-weekly injectionAround 20% over 72 weeks at 15 mg (SURMOUNT-1 trial)
The Wegovy pill (oral semaglutide)Acts on the GLP-1 receptorOnce-daily tabletAround 17% over 64 weeks (OASIS 4 trial)
Foundayo (orforglipron)Acts on the GLP-1 receptorOnce-daily tabletAround 12% on average (ATTAIN-1 trial)
 

Ozempic contains the same active ingredient as the Wegovy injection and is not listed because it is approved for type 2 diabetes. Two of our articles look at these options side by side: the difference between Ozempic and Wegovy and Mounjaro, Ozempic and Wegovy compared.

Your first consultation

Your first appointment is a full medical assessment, not simply a prescription visit. Your endocrinologist will review your medical history and any relevant blood tests, assess your weight and metabolic health, and discuss whether the Wegovy injection or another weight loss treatment is the right option for you.

Where possible, your first appointment takes place in person at Endocare’s Dubai clinic, as the physical examination and body composition analysis cannot be completed remotely. Your endocrinologist will review blood tests from the last three months before prescribing.

If your results are out of date, the clinic can arrange the required tests. If they are current, your assessment and prescription can usually be completed at your first appointment. Medication delivery is free across the UAE and typically arrives the same day.

Our pages on Wegovy in Dubai and Wegovy in Abu Dhabi explain how to access treatment in each city.

Monthly follow-ups

Monthly follow-up appointments can be held in person at the clinic or online. At each follow-up, your endocrinologist will review your progress and agree any change in dose with you. Endocare’s lifestyle coaches and our clinical nutritionist will work with you on nutrition, movement, sleep and stress.

At Endocare, body composition analysis is included free of charge at every consultation. Body composition analysis estimates body fat, muscle mass and body water. Repeated measurements help your endocrinologist understand how your body is changing beyond the number on the scale.

No, although both contain semaglutide. Ozempic is approved for type 2 diabetes, and Wegovy is the semaglutide medication approved for weight management. At Endocare, we consider Ozempic for weight management only in patients with type 2 diabetes or prediabetes. Ozempic is not approved for weight management or for prediabetes, so using it for weight management outside the treatment of type 2 diabetes, including in prediabetes, is off-label.

Yes, from the age of 12. The Wegovy injection is approved for adolescents aged 12 and older with obesity. Mounjaro and Foundayo are approved for weight management in adults only. Whether treatment is appropriate for a young person is decided by a doctor after a full assessment.

There is no fixed end date. Your endocrinologist will review at each follow-up whether to continue or adjust the dose, and will help plan whether and how to stop treatment when the time comes.

Your endocrinologist can discuss whether a switch is appropriate for you, because the tablet and the injection follow different dose steps. Our article on switching from your weight loss injection to a pill explains the considerations.

Some weight regain is possible after stopping, as appetite can return. When it is time to come off the medication, your endocrinologist will help plan whether and how to stop treatment and what support you will need afterwards. A gradual reduction in dose is an individual clinical approach, not a proven standard of care, and it has not been shown to prevent weight regain. Our guide on how to stop a weight loss injection safely explains the options.

The Wegovy injection is available in the UAE only on prescription, after a doctor has assessed whether it is appropriate for you. We recommend obtaining it only through a licensed pharmacy and never from unregulated online sellers.

Book a Wegovy consultation at Endocare

At our Dubai clinic, your endocrinologist will assess you, review your blood tests and discuss whether the Wegovy injection is appropriate for you. You can book a weight loss consultation on +971 4 285 3885 or send us a message on WhatsApp.

Book Your Consultation

Select your location